JEIL PHARMA HOLDINGS INC. Q3 operating loss of KRW 3.4 billion, revenue KRW 156.7 billion, swinging to a loss
AI summary · Not investment advice
In Q3, Jeil Pharma Holdings sold KRW 156.7 billion worth and lost KRW 3.4 billion from its main business, after earning KRW 18.1 billion a year earlier.
Operating profit · 3 months
KRW -3.4 billion
Key facts
- Revenue (3 months)
- KRW 156.7 billion
- Net income (3 months)
- KRW -9.4 billion
- Period
- Q3 (cumulative 2026.01.01 ~ 2026.09.30)
- Revenue (prior-year 3 months)
- KRW 161.4 billion
- Revenue (year to date)
- KRW 471.8 billion
- Operating profit (prior-year 3 months)
- KRW 18.1 billion
- Operating profit (year to date)
- KRW -9.8 billion
- Net income (prior-year 3 months)
- KRW 14.2 billion
- Net income (year to date)
- KRW -11.1 billion
Commentary
AI commentary · Not investment advice
What happened
Jeil Pharma Holdings reported its consolidated results for the third quarter of 2026. Sales for the latest 3 months were KRW 156.7 billion. That is 2.9% lower than the same 3 months a year earlier and 4.8% lower than the previous quarter.
In the company's terms
Operating profit (money earned from the core business) for the 3 months was a loss of KRW 3.4 billion, a swing from a profit of KRW 18.1 billion a year earlier. Net income (the final profit after taxes and all other costs) was a loss of KRW 9.4 billion, also a swing from a profit of KRW 14.2 billion a year earlier.
What changes for shareholders
For the year to date, from January 1 to September 30, sales were KRW 471.8 billion. Operating profit was a loss of KRW 9.8 billion. Net income was a loss of KRW 11.1 billion.
Comments
No comments yet
Comments from shareholders will appear here.
Ad
Verify your holdings and catch the next disclosure
Verify the stocks you hold and get new disclosures as app alerts.

App design sample
Get the next disclosure as an app alert
Get app alerts for new disclosures and stake changes on your watchlist
J